This product belongs to the 4-nitrogen steroid hormone compound, which is a specific type II 5α-reductase competitive inhibitor, inhibiting the conversion of peripheral testosterone into dihydrotestosterone, and reducing the level of dihydrotestosterone in blood, prostate, skin and other tissues. By reducing the level of dihydrotestosterone in blood and prostate tissue, it inhibits prostate hyperplasia and improves the related clinical symptoms of benign prostatic hyperplasia.

This product is a brain metabolism improving drug, which is a cyclic derivative of r-aminobutyric acid. It has the effect of resisting brain function damage caused by physical and chemical factors. It can promote ATP in the brain, promote acetylcholine synthesis and positively enhance the conduction of nerve excitement, and has the effect of promoting brain metabolism. It can resist brain function damage caused by physical and chemical factors. It has an improving effect on retrograde hyperactivity caused by hypoxia. It can enhance memory and improve learning ability.

This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.

This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.